Integrace

What Integrace does

Integrace Health (Integrace Private Limited) is a therapy-focused pharmaceutical company headquartered in Mumbai, India, founded in 2018 and operating across three therapeutic verticals: Musculoskeletal Disorders and Orthopaedics, Pain Management, and Women's Health (Gynaecology and Obstetrics). The company markets 65+ branded generic and specialty pharmaceutical products across prescription and OTC categories, including bone-health supplements (BON K2, BON NXT, BON DK), neuropathic pain therapies (Dubinor), gastroenterology products (ESOZ, ESOZ-D, ESOZ L), women's health brands (Mifegest, Cytolog, Dubagest, Mumfer), and an Ayurvedic OTC pain relief line (Sensur). Its proprietary MPD2 (Micronized Pellet Duality) delivery technology supports products such as ESOZ-D, enabling differentiated pellet-based drug release profiles. Integrace was built through a series of business and brand acquisitions from Glenmark (Ortho business 2018, Gynae business 2020) and Zydus (Mifegest and Cytolog in 2021), with the manufacturing transition from Glenmark completed in March 2021.

The company operates a sales-led go-to-market model anchored on a direct field sales organization of medical representatives organized by therapy area, calling on doctors, clinics, and hospitals across India. It complements this with the VKonnect Health digital engagement platform for healthcare professional interactions, scientific events (e.g., BOOT), and a growing OTC retail distribution channel. Five of its brands rank #1 in their respective therapy areas, and the company has been ranked 67th in the IPM (Indian Pharmaceutical Market) for three consecutive years, up from rank 98 in 2018. The company reports impacting over 10 lakh (1 million) lives since inception and targets becoming a Top 20 Indian pharmaceutical company by 2030.

Integrace is privately held (Private Limited entity), backed by True North as the founding private equity sponsor and Temasek (Singapore Sovereign Fund), which invested in October 2021. Headcount is 501-1,000 employees, with senior leadership drawn from Piramal, Abbott, Lupin, Glenmark, Emcure, and Hindustan Lever. Revenue is not publicly disclosed, and pricing is quote-based and institutional. The company is single-geography, operating only in India.

Name

Integrace

Legal name

Integrace Private Limited

Website

https://www.integracehealth.com/

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Integrace Health is an Indian therapy-focused pharmaceutical company founded in 2018, marketing 65+ branded generic and OTC products across Musculoskeletal Disorders, Pain Management, and Women's Health, sold via a direct field sales force to doctors, hospitals, and pharmacies across India.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421), Health and Personal Care Retailers (456)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Retail-Drug Stores And Proprietary Stores (5912)

akta.pro primary industry

Pain Relief & Anti-Inflammatory (Analgesics) (HLAIADAA)

akta.pro secondary industries

Women’s Health (OTC Gynecologic) (HLAIADAJ), Cold, Flu & Cough Remedies (HLAIADAB), First Aid & Wound Care (HLAIADAM), OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC), Sleep, Stress & Mood OTC (Sleep Aids, Melatonin OTC, Calm/Stress Relief) (CRADAMAJ)

Keywords

• Pharmaceutical products
• Musculoskeletal health
• Pain management
• Women's health pharmaceuticals
• Gynecology products

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Supply Chain, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Integrace Health generates revenue through the sale of prescription pharmaceutical products (branded generics and specialty drugs) across Orthopaedics, Gynaecology/Obstetrics, and OTC categories. The company sells through its direct field sales force to doctors, hospitals, and pharmacies across India.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Integrace Health manufactures and markets branded pharmaceutical and over-the-counter (OTC) products focused on three therapy verticals: Musculoskeletal Disorders, Pain Management, and Women's Health (Gynaecology and Obstetrics). The portfolio includes 65+ prescription drugs, Ayurvedic OTC pain relief products, diagnostics, and nutritional supplements distributed across India through a direct field sales force targeting prescribers, hospitals, and retail pharmacies.

Product overview

Integrace is a therapy-focused pharmaceutical company providing novel solutions in Musculoskeletal Disorders, Pain Management, and Women's Health. The company operates as a single-brand portfolio with three main product categories: Orthopaedic (BON K2, UltraHeal, Dubinor, Stiloz, ESOZ variants, BON NXT, BON DK products, Dubinor Ointment, LIZOLID), Gynaecology and Obstetrics (Mifegest, Mifegest KIT, Cytolog, Dubagest, Dubagest SR, Dydro 1, Fenza, Mumfer XT, Mumfer MAX), and OTC products (Sensur Ayurvedic pain relief line, Accurate pregnancy/ovulation tests, Collasmart collagen, BON ISO WHEY and BON PURE WHEY protein supplements). Founded in 2018, it is the youngest Top 70 pharma company in India with 5 brands ranked #1 in their respective therapy areas. Products are primarily distributed through prescription/pharmaceutical channels with some OTC availability.

Differentiator

Problem solved

Functional benefit

Brands

• VKonnect: A scientific offerings platform under Integrace Health for healthcare professional engagement and medical education.
• Integrace

Products and services

• Stiloz

Quantifiable outcome

• 10,00,000+ lives impacted since 2018
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• ZyduscoreOthers · 1 September 2021In September 2021, Integrace acquired brands Mifegest and Cytolog from Zydus. These brands strengthened the Women's Health portfolio, with Cytolog ranking #1 in IPM. This acquisition contributed to the company's rise from Rank 63 to Rank 67 in IPM.
• GlenmarkcoreOthers · 1 March 2021In March 2021, Integrace completed the transition of manufacturing facilities from Glenmark and completed rebranding. Prior to this, in October 2018 the company acquired Glenmark's Ortho business (Rank 98 in IPM), and in February 2020 acquired Glenmark's Gynae business. Glenmark was the original parent/seller of the business assets that became Integrace.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Ajanta Pharma: Mid-sized Indian pharma with branded generics sold via field force across specialties. Comparable in scale, India-and-emerging-markets orientation, and therapy-driven product portfolio structure to Integrace.
• Mankind Pharma: One of India's largest domestic-focused pharma companies with a strong branded generics + OTC portfolio sold through a pan-India field force. Closely comparable to Integrace in target market, channel model (medical representatives to doctors), and therapy breadth across chronic and acute categories.
• Eris Lifesciences: India-focused, therapy-driven branded generics company concentrated in chronic categories (cardio-metabolic, women's health, dermatology). Highly comparable to Integrace in strategy of picking focused therapy verticals, building specialty field forces, and pursuing brand acquisitions to accelerate growth.
• JB Chemicals & Pharmaceuticals: Indian pharma company with a branded prescription portfolio and OTC consumer brands distributed through doctors and retail pharmacies. Comparable channel model and mix of Rx + OTC products to Integrace.
• Alembic Pharmaceuticals: Indian branded-generics and specialty pharma company selling across therapeutic categories. Comparable in scale, India-centric field-force distribution, and branded-generic model to Integrace.
• Unichem Laboratories: Mid-sized Indian pharma with branded generics across multiple therapy areas distributed through field force. Comparable scale and channel strategy to Integrace.

Broad incumbents

• Glenmark Pharmaceuticals: Large Indian pharma with broad therapy footprint across India, US, and emerging markets. Directly comparable as the seller of Integrace's founding Ortho and Gynae businesses; operates in overlapping therapy areas (Ortho, Gynae, Pain) with a much wider portfolio.
• Zydus Lifesciences (Cadila Healthcare): Large Indian pharma with broad therapy and consumer health presence. Directly comparable as the seller of Mifegest and Cytolog to Integrace; competes in women's health and broader chronic/acute categories.
• Lupin: Large Indian pharma with strong branded generics presence across multiple therapy areas including women's health and orthopaedics. Comparable at category level, though significantly larger and more diversified globally.
• Torrent Pharmaceuticals: Large Indian pharma with branded generics across chronic and acute categories. Operates in overlapping therapy areas (orthopaedics, gynaecology, pain) with a broader portfolio and international presence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/integraceh

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Integrace